Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 5/2005

01-11-2005 | Letter to the Editor

Oligodendroglioma with neurocytic differentiation and characteristic loss of heterozygosity on chromosomes 1p and 19q

Authors: Istvan Vajtai, Marlene Arnold, Erik Vassella

Published in: Acta Neuropathologica | Issue 5/2005

Login to get access

Excerpt

Neuronal differentiation in neoplasms of the central nervous system (CNS) has been known to occur either as a polyphenotypic trait of primitive neuroectodermal tumors (PNET) or in the form of composite lesions incorporating well-defined neuronal and glial elements (e.g., ganglioglioma). …
Literature
1.
Berger F, Gay E, Pelletier L, Tropel P, Wion D (2004) Development of gliomas: potential role of asymmetrical cell division of neural stem cells. Lancet Oncol 5:511–514CrossRefPubMed
2.
Brat DJ, Scheithauer BW, Eberhart CG, Burger PC (2001) Extraventricular neurocytomas. Pathologic features and clinical outcome. Am J Surg Pathol 25:1252–1260CrossRefPubMed
3.
Cenacchi G, Giangaspero F (2004) Emerging tumor entities and variants of CNS neoplasms. J Neuropathol Exp Neurol 63:185–192PubMed
4.
Deimling A von, Kleihues P, Saremaslani P, Yasargil MG, Spoerri O, Sudhof TC, Wiestler OD (1991) Histogenesis and differentiation potential of central neurocytomas. Lab Invest 64:585–591PubMed
5.
Mrak RE, Yasargil MG, Mohapatra G, Earel J, Louis DN (2004) Atypical extraventricular neurocytoma with oligodendroglioma-like spread and an unusual pattern of chromosome 1P and 19Q loss. Hum Pathol 35:1156–1159CrossRefPubMed
6.
Perry A, Scheithauer BW, Macaulay RJB, Raffel C, Roth KA, Kros JM (2002) Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 61:947–955PubMed
7.
Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW (2003) Ancillary FISH analysis for 1p and 19q status: Preliminary observations in 250 gliomas and oligodendroglioma mimics. Front Biosci 8:1-9
8.
Varlet P, Soni D, Miquel C, Roux FX, Meder JF, Chneiweiss H, Daumas-Duport C (2004) New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery 55:1377–1392CrossRefPubMed
9.
Williams BP, Read J, Price J (1991) The generation of neurons and oligodendrocytes from a common precursor. Neuron 7:685–693CrossRefPubMed
Metadata
Title
Oligodendroglioma with neurocytic differentiation and characteristic loss of heterozygosity on chromosomes 1p and 19q
Authors
Istvan Vajtai
Marlene Arnold
Erik Vassella
Publication date
01-11-2005
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 5/2005
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-005-1091-8

Other articles of this Issue 5/2005

Acta Neuropathologica 5/2005 Go to the issue

Regular Paper

Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation

Regular Paper

Extensive cortico-subcortical lesions in Wilson’s disease: clinico-pathological study of two cases

Regular Paper

Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis

Regular Paper

Neuropathologic characteristics of spinal cord lesions in sporadic Creutzfeldt-Jakob disease

Review

The extracellular space and matrix of gliomas

Regular Paper

Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient’s age but not with tumor’s clinicopathological pathway